p66 Shc Tumor Levels Show a Strong Prognostic Correlation with Disease Outcome in Stage IIA Colon Cancer
Open Access
- 1 October 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 13 (19) , 5798-5804
- https://doi.org/10.1158/1078-0432.ccr-07-0073
Abstract
Purpose: Most stage IIA colon cancer patients receive no adjuvant therapy despite an estimated 15% risk of disease-related death within 5 years of resection. Prognostication of disease outcome would benefit the clinician by categorizing patients with stage IIA disease by risk. The abundance of the signal transduction proteins p66 Shc and tyrosine-phosphorylated (PY)-Shc in tumor cells is a prognostic indicator of disease outcome in breast cancer, suggesting that Shc analysis may provide prognostic information in stage IIA colon cancer.Keywords
This publication has 24 references indexed in Scilit:
- ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal CancerJournal of Clinical Oncology, 2006
- Demographics and tumor characteristics of colorectal cancers in the United States, 1998–2001Cancer, 2006
- The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer.Clinical Cancer Research, 2006
- Staging and Prognosis of Colon CancerSurgical Oncology Clinics of North America, 2006
- Pharmacogenomics in colorectal carcinomas: Future perspectives in personalized therapyJournal of Cellular Physiology, 2005
- Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray studyLaboratory Investigation, 2005
- p66SHC: The apoptotic side of Shc proteinsApoptosis, 2005
- High Frequency of Mutations of the PIK3CA Gene in Human CancersScience, 2004
- Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancerGut, 2004
- p53, guardian of the genomeNature, 1992